MedTrace Logo

Maqui Berry Extract and Omega-3 Fatty Acids for Cytokine Reduction

NCT04914312 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-10-17

No results posted yet for this study

Summary

The purpose of this trial is to determine the effect of maqui extract plus omega-3 fatty acids compared to a placebo for reducing inflammatory cytokine levels in older, obese adults.

Conditions

Interventions

DIETARY_SUPPLEMENT

Maqui berry/omeg-3 fatty acids

2 capsules BID per day containing a total of 600 mg of Maqui extract; 4 capsules per day supplying a total of 2000 mg EPA and 1000 mg DHA

DIETARY_SUPPLEMENT

Placebos

4 olive oil soft gelatin capsules and inert two-piece capsules containing maltodextrin

Sponsors & Collaborators

  • Arizona State University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-15
Primary Completion
2023-07-30
Completion
2023-08-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04914312 on ClinicalTrials.gov